Once the company receives the SPA for their pivotal MM Phase 3 trial -- whenever that happens -- I would not be surprised to see high profile biotechnology equity research analysts (like a Dr. Mark Monane-type) initiate coverage (without management having to put an implicit or explicit investment banking relationship in place with the analyst's firm).
Such coverage would be most welcome!
No comments:
Post a Comment